CCS
LAB icon

Crosspoint Capital Strategies’s Standard BioTools LAB Stock Holding History

Crosspoint Capital Strategies’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-676
Closed -$16K – 840
2015
Q2 		$16K Buy
+676
New +$21.3K ﹤0.01% 447
2015
Q1 		– Sell
-338
Closed -$11K – 640
2014
Q4 		$11K Buy
+338
New +$9.57K ﹤0.01% 515
2014
Q2 		– Sell
-130,029
Closed -$5.73M – 575
2014
Q1 		$5.73M Buy
130,029
+1,046
+0.8% +$46K 2.32% 9
2013
Q4 		$6.15M Buy
+128,983
New +$3.8M 2.05% 11

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Crosspoint Capital Strategies's LAB Position: Q3 2015 in Review

Crosspoint Capital Strategies sold out of Standard BioTools (LAB) in Q3 2015, closing a stake of 676 shares — an estimated $16K sold.

Crosspoint Capital Strategies first reported a position in LAB in Q4 2013 and held it in 4 quarters. The position peaked at $6.15M in Q4 2013. 109 funds tracked by Wall St. Rank hold LAB as of Q3 2015.

  • Crosspoint Capital Strategies reported no remaining Standard BioTools position as of Q3 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 676 Standard BioTools shares in Q3 2015, an estimated $16K.
  • Crosspoint Capital Strategies first reported a position in Standard BioTools in Q4 2013 and held it in 4 quarters.
  • Crosspoint Capital Strategies's Standard BioTools position peaked at $6.15M in Q4 2013.
  • 109 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2015, filed 25 Nov 2015.